ENUMERATION AND CHARACTERISATION OF CIRCULATING TUMOR CELLS (CTC) IN PATIENTS WITH SOLID MALIGNANCIES

ENUMERATION AND CHARACTERISATION OF CIRCULATING TUMOR CELLS (CTC) IN PATIENTS WITH SOLID MALIGNANCIES - Circulating Tumor Cells, solid malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30560

Enrollment

900

Registered

2007-10-17

Start date

2008-01-17

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients suffering from one of the below mentioned solid malignancies. For patients with metastatic disease, only those who will be treated with first line systemic treatment will be recruited. o metastatic breast cancer (number 100-150) o localized breast cancer (number 100-150) o metastatic colorectal cancer (number 100-150) o localized colorectal cancer (number 100-150) o metastatic prostate cancer (number 100-150) o metastatic other tumor types such as testicular cancer, soft tissue sarcoma, renal cell carcinoma, lung carcinoma (in total maximum number 100-150);- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.;- Before patient randomization, written informed consent must be given and documented to ICH/EU GCP, and national/local regulatory requirements and the local rules followed in the institution

Exclusion criteria

Exclusion criteria: Geen

Design outcomes

Primary

Measure	Time frame
To enumarate and characterize CTC's.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results